{"id":11093,"date":"2022-11-29T03:02:30","date_gmt":"2022-11-29T03:02:30","guid":{"rendered":"https:\/\/marylanddailygazette.com\/endometrial-cancer-market-to-register-incremental-growth-during-the-forecast-period-2022-32-key-players-oncoceutics-novartis-chimerix-karyopharm-incyte-pfizer-astrazeneca-glaxosmi\/"},"modified":"2022-11-29T03:02:30","modified_gmt":"2022-11-29T03:02:30","slug":"endometrial-cancer-market-to-register-incremental-growth-during-the-forecast-period-2022-32-key-players-oncoceutics-novartis-chimerix-karyopharm-incyte-pfizer-astrazeneca-glaxosmi","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/endometrial-cancer-market-to-register-incremental-growth-during-the-forecast-period-2022-32-key-players-oncoceutics-novartis-chimerix-karyopharm-incyte-pfizer-astrazeneca-glaxosmi\/","title":{"rendered":"Endometrial Cancer Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players \u2013 Oncoceutics, Novartis, Chimerix, Karyopharm, Incyte, Pfizer, AstraZeneca, GlaxoSmithKline"},"content":{"rendered":"<p><a href=\"https:\/\/www.digitaljournal.com\/pr\/endometrial-cancer-market-to-register-incremental-growth-during-the-forecast-period-2022-32-key-players-oncoceutics-novartis-chimerix-karyopharm-incyte-pfizer-astrazeneca-glaxosmi\">Endometrial Cancer Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players \u2013 Oncoceutics, Novartis, Chimerix, Karyopharm, Incyte, Pfizer, AstraZeneca, GlaxoSmithKline<\/a><\/p>\n<div readability=\"6\"><a href=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/11\/7dXERc.jpeg\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Endometrial Cancer Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players - Oncoceutics, Novartis, Chimerix, Karyopharm, Incyte, Pfizer, AstraZeneca, GlaxoSmithKline\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/11\/7dXERc.jpeg\" alt=\"Endometrial Cancer Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players - Oncoceutics, Novartis, Chimerix, Karyopharm, Incyte, Pfizer, AstraZeneca, GlaxoSmithKline\" width=\"225\"><\/a><\/p>\n<div class=\"quotes\" readability=\"7\">\n<p>\u201cDelveinsight Business Research LLP\u201d<\/p>\n<\/div>\n<\/div>\n<p>As per DelveInsight, the Endometrial Cancer therapeutics market is anticipated to increase in the coming years owing to the rising prevalent population of Endometrial Cancer patients in the 7MM and the expected entry of emerging therapies such as Kymriah, Yescarta, and others.<\/p>\n<p dir=\"ltr\">DelveInsight\u2019s \u201c<strong>Endometrial Cancer Market Insights, Epidemiology, and Market Forecast 2032<\/strong>\u201d report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Endometrial Cancer market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p dir=\"ltr\">The Endometrial Cancer market report covers emerging drugs, current treatment practices, market share of individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers &amp; barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p dir=\"ltr\"><img decoding=\"async\" title=\"Endometrial Cancer Market\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/11\/EoSFDS.jpg\" alt=\"Endometrial Cancer Market\"><\/p>\n<p dir=\"ltr\"><strong>Endometrial Cancer: An Overview<\/strong><\/p>\n<p>Endometrial cancer (a type of Uterine Cancer) starts when cells in the endometrium start to grow out of control. The most common type of endometrial cancer (type 1) grows slowly. It is most often found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Some of the risk factors for endometrial cancer include the following: age, level of hormones, being overweight, and genetics.<\/p>\n<p><strong>Endometrial Cancer Market Key Facts<\/strong><\/p>\n<ul readability=\"5.5\">\n<li dir=\"ltr\" readability=\"3\">\n<p dir=\"ltr\"><em>As per Cancer Research UK, there are around<strong> 9,400&nbsp;new uterine cancer cases<\/strong> in the UK every year, that\u2019s 26 every day (2015-2017).<\/em><\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"2\">\n<p dir=\"ltr\"><em>According to the National Cancer Institute, approximately<strong> 3 in 100 women<\/strong> will be diagnosed with uterine cancer at some point in their lives. More than <strong>80 percent of people<\/strong> with uterine cancer survive for five years or longer after receiving the diagnosis.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"3\">\n<p dir=\"ltr\"><em>The American Cancer Society estimates for cancer of the uterus in the United States for 2021 were: About <strong>66,570 new cases of cancer<\/strong> of the body of the uterus (uterine body or corpus) will be diagnosed. About <strong>12,940 women<\/strong> will die from cancers of the uterine body.<\/em><\/p>\n<\/li>\n<\/ul>\n<p dir=\"ltr\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/endometrial-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Endometrial Cancer Market<\/strong><\/a><\/p>\n<p dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Endometrial Cancer market size<\/strong> by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies set to impact the market dynamics.<\/p>\n<p dir=\"ltr\">The report gives complete detail of the <strong>Endometrial Cancer market trend<\/strong> for each marketed drug and mid &amp; late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.<\/p>\n<p dir=\"ltr\"><strong>Endometrial Cancer Epidemiology Assessment&nbsp;<\/strong><\/p>\n<p dir=\"ltr\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.&nbsp;<\/p>\n<p dir=\"ltr\"><strong>Endometrial Cancer Epidemiology Segmentation<\/strong><\/p>\n<ul readability=\"0\">\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Total Incident Cases of Endometrial Cancer<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Stage-specific Incident Cases of Endometrial Cancer<\/p>\n<\/li>\n<li dir=\"ltr\" readability=\"-1\">\n<p dir=\"ltr\">Age-specific Cases of Endometrial Cancer<\/p>\n<\/li>\n<\/ul>\n<p dir=\"ltr\"><strong>Endometrial Cancer Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Endometrial Cancer market<\/strong> or expected to get launched during the study period. The analysis covers the Endometrial Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p dir=\"ltr\">The report also covers the <strong>Endometrial Cancer Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p dir=\"ltr\"><strong>Learn How Endometrial Cancer Market Will Evolve by 2032 @&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/endometrial-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/endometrial-cancer-market<\/a><\/strong><\/p>\n<p dir=\"ltr\"><strong>Endometrial Cancer Therapeutics Analysis<\/strong><\/p>\n<p>When a person is diagnosed with endometrial cancer, the cancer stage affects the treatment options and the long-term outlook. Endometrial cancer is easier to treat in the early stages of the condition. Surgery, radiation therapy, chemotherapy, and hormone therapy are some of the treatment options available for treating Endometrial Cancer.<\/p>\n<p dir=\"ltr\"><em>Significant developments have been made in Endometrial Cancer therapy over the past several decades. Many monotherapies and combinations are in trial.&nbsp;<\/em><em>Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years.<\/em><\/p>\n<p dir=\"ltr\"><strong>Some of the Key Companies in the Endometrial Cancer Market Include:<\/strong><\/p>\n<p dir=\"ltr\"><strong><em>Incyte Corp, Pfizer, AstraZeneca, Oncoceutics, GlaxoSmithKline, Roche, Eli Lily, Novartis, Chimerix, Karyopharm Therapeutics, and others.<\/em><\/strong><\/p>\n<p dir=\"ltr\"><strong>Endometrial Cancer Therapies covered in the report include:<\/strong><\/p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ZW25<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ONC201<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Avelumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Abemaciclib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Selinexor<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Retifanlimab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Dostarlimab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Atezolizumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Durvalumab<\/p>\n<\/li>\n<\/ul>\n<p dir=\"ltr\">And many more.&nbsp;<\/p>\n<p dir=\"ltr\"><strong>Further Emerging Drugs &amp; Key Companies are Covered in the Report. Download the Sample PDF to Learn More:&nbsp;<\/strong><\/p>\n<p dir=\"ltr\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/endometrial-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/endometrial-cancer-market<\/strong><\/a><\/p>\n<p dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p dir=\"ltr\">1. Key Insights<\/p>\n<p dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p dir=\"ltr\">3. Endometrial Cancer Competitive Intelligence Analysis<\/p>\n<p dir=\"ltr\">4. Endometrial Cancer Market Overview at a Glance<\/p>\n<p dir=\"ltr\">5. Endometrial Cancer Disease Background and Overview<\/p>\n<p dir=\"ltr\">6. Endometrial Cancer Patient Journey<\/p>\n<p dir=\"ltr\">7. Endometrial Cancer Epidemiology and Patient Population (In the US, EU5, and Japan)<\/p>\n<p dir=\"ltr\">8. Endometrial Cancer Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p dir=\"ltr\">9. Endometrial Cancer Unmet Needs<\/p>\n<p dir=\"ltr\">10. Key Endpoints of Endometrial Cancer Treatment<\/p>\n<p dir=\"ltr\">11. Endometrial Cancer Marketed Products<\/p>\n<p dir=\"ltr\">12. Endometrial Cancer Emerging Drugs and Latest Therapeutic Advances<\/p>\n<p dir=\"ltr\">13. Endometrial Cancer Seven Major Market Analysis<\/p>\n<p dir=\"ltr\">14. Attribute Analysis<\/p>\n<p dir=\"ltr\">15. Endometrial Cancer Market Outlook (In US, EU5, and Japan)<\/p>\n<p dir=\"ltr\">16. Endometrial Cancer Access and Reimbursement Overview<\/p>\n<p dir=\"ltr\">17. KOL Views on the Endometrial Cancer Market<\/p>\n<p dir=\"ltr\">18. Endometrial Cancer Market Drivers<\/p>\n<p dir=\"ltr\">19. Endometrial Cancer Market Barriers<\/p>\n<p dir=\"ltr\">20. Appendix<\/p>\n<p dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p dir=\"ltr\">22. Disclaimer<\/p>\n<p dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p dir=\"ltr\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/endometrial-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/endometrial-cancer-market<\/strong><\/a><\/p>\n<p dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p dir=\"ltr\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/endometrial-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Endometrial Cancer Pipeline Insights<\/strong><\/a><\/p>\n<p dir=\"ltr\">Endometrial Cancer Pipeline Insights, 2022 report by DelveInsight, outlays comprehensive insights of present clinical development scenario and growth prospects across the Endometrial Cancer Market.<\/p>\n<p dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span>Media Contact<\/span><br \/><strong>Company Name:<\/strong> DelveInsight Business Research LLP<br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"http:\/\/www.universalpressrelease.com\/?pr=endometrial-cancer-market-to-register-incremental-growth-during-the-forecast-period-202232-key-players-oncoceutics-novartis-chimerix-karyopharm-incyte-pfizer-astrazeneca-glaxosmithkline&amp;type=pra\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432 <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=endometrial-cancer-market-to-register-incremental-growth-during-the-forecast-period-202232-key-players-oncoceutics-novartis-chimerix-karyopharm-incyte-pfizer-astrazeneca-glaxosmithkline\" alt width=\"1px\" height=\"1px\"><\/p>\n<p>Published Mon, 28 Nov 2022 20:30:17 -0600<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Endometrial Cancer Market to Register Incremental Growth During the Forecast Period (2022-32) | Key Players \u2013 Oncoceutics, Novartis, Chimerix, Karyopharm, Incyte, Pfizer, AstraZeneca, GlaxoSmithKline \u201cDelveinsight Business Research LLP\u201d As per DelveInsight, the Endometrial Cancer therapeutics market is anticipated to increase in the coming years owing to the rising prevalent population of Endometrial Cancer patients in [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":11091,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/11093"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=11093"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/11093\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/11091"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=11093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=11093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=11093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}